Nesta página
01ABUS preço
02Instantâneo
03Gráfico
04Divisões de Ações
05Sobre
06Desempenho
07Avaliação e rácios
14Lucros
15Fundamentos Completos
16Demonstrações
17Investidores institucionais (13F)
18Ativistas e proprietários de 5%+
19Executivos da empresa
20Participação em ETFs
21Consenso
22Pares
23Notícias
26Minhas Métricas
ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 12, 2026
$4,45
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$3,67mínima 52 sem
$5,45máxima 52 sem
Capitalização de Mercado (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Receita (TTM)
$182M
seus distintivos
Intervalo 52 Semanas
$4–$5
Classificação do Analista
STRONG BUY
Preço-Alvo
$5
P/E
5.6
ROE
89.6%
Margem de Lucro Líquido
84.2%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
ABUS Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$4.45
Capitalização de Mercado (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Receita (TTM)
$182M
ROE (TTM)
89.6%
Intervalo 52 Semanas
$4–$5
ABUS Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Divisões de Ações
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 4 de Novembro de 2010 | 1-for-5 | Reverso |
Sobre Arbutus Biopharma Corporation - Common Stock Visão geral da empresa da Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários19
paísCA
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$14M2016-12-31 → 2025-12-31
EPS$-0.172016-12-31 → 2025-12-31
Fluxo de caixa livre$-40M2016-12-31 → 2025-12-31
Margem líquida84.2%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | ABUS | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | 5.6média 5A ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.8média 5A ≈50.1 | ≈50.1 | 10.3 | Subvalorizado | |
| P/B (MRQ) | 3.4média 5A ≈5.7 | ≈5.7 | 3.7 | Valor justo | |
| Price / FCF (Preço / FCF) | -22.1média 5A ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow (Preço / Fluxo de Caixa) | -22.1média 5A ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book (Preço / Valor Patrimonial Tangível) | 11.4média 5A ≈5.7 | ≈5.7 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | ABUS | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 82.0%média 5A ≈-555.0% | ≈-555.0% | -588.2% | Em linha | |
| EBITDA Margin (Margem EBITDA) | -271.0%média 5A ≈-555.0% | ≈-555.0% | -588.2% | Em linha | |
| Margem de Lucro Líquido (TTM) | 84.2%média 5A ≈-528.9% | ≈-528.9% | -507.2% | Em linha | |
| ROA (TTM) | 81.1%média 5A ≈-40.5% | ≈-40.5% | -29.6% | Em linha | |
| ROE (TTM) | 89.6%média 5A ≈-55.0% | ≈-55.0% | -42.0% | Em linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | ABUS | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 81.4média 5A ≈9.7 | ≈9.7 | 9.6 | Liquidez forte | |
| Quick Ratio (Índice de Liquidez Seca) | 15.5média 5A ≈9.5 | ≈9.5 | 6.6 | Em linha |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | ABUS | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 128.2%média 5A ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | -28.8%média 5A ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 15.3% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | ABUS | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.1média 5A ≈0.1 | ≈0.1 | 0.2 | Fraco | |
| Receivables Turnover (Giro de Contas a Receber) | 7.3média 5A ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$741.2K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
581.5%
Próximo relatório
Nov 11, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| 31 de Março de 2026 | Mai 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| 31 de Dezembro de 2025 | $-0.02 | $-0.04 | 44.0% | |
| 30 de Setembro de 2025 | $-0.04 | $-0.03 | -26.6% | |
| 30 de Junho de 2025 | $0.01 | $-0.05 | 120.6% | |
| 31 de Março de 2025 | $-0.13 | $-0.11 | -23.2% | |
| 31 de Dezembro de 2024 | $-0.07 | $-0.08 | 14.2% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $14M | $6M | $18M | $39M | $11M |
| Margem Operacional % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Lucro líquido | $-34M | $-70M | $-73M | $-69M | $-76M |
| EPS Diluído | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Índice de Liquidez Seca | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-40M | $-65M | $-87M | $-36M | $-68M |
Investidores institucionais (13F) 187 declarantes · $719.6M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
187
Valor detido
$719.6M
Novas posições
35
Posições encerradas
23
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 35 (+3 vs trimestre anterior) | 23 (-8 vs trimestre anterior) | 62 (+13 vs trimestre anterior) | 42 (-10 vs trimestre anterior) | +466K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Two Seas Capital LP | $91.658.798 | 19.095.583 | 12,74% | Ações |
| MORGAN STANLEY | $84.951.868 | 17.698.305 | 11,81% | Ações |
| Whitefort Capital Management, LP | $75.812.453 | 15.794.261 | 10,54% | Ações |
| BlackRock, Inc. | $66.077.140 | 13.766.071 | 9,18% | Ações |
| VANGUARD GROUP INC | $44.456.122 | 9.242.437 | 6,18% | Ações |
| STATE STREET CORP | $37.772.059 | 7.869.179 | 5,25% | Ações |
| Rubric Capital Management LP | $36.158.098 | 7.532.937 | 5,03% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.651.259 | 7.010.679 | 4,68% | Ações |
| BARCLAYS PLC | $20.197.987 | 4.207.914 | 2,81% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $19.769.043 | 4.117.691 | 2,75% | Ações |
| GOLDMAN SACHS GROUP INC | $16.832.650 | 3.506.802 | 2,34% | Ações |
| BANK OF AMERICA CORP /DE/ | $12.701.745 | 2.646.197 | 1,77% | Ações |
| BlackBarn Capital Partners LP | $12.000.000 | 2.500.000 | 1,67% | Ações |
| Legal & General Group Plc | $11.837.409 | 2.466.127 | 1,65% | Ações |
| Woodline Partners LP | $10.952.909 | 2.281.856 | 1,52% | Ações |
| Jefferies Financial Group Inc. | $8.216.026 | 1.711.672 | 1,14% | Ações |
| NOMURA HOLDINGS INC | $7.857.989 | 1.637.081 | 1,09% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.398.998 | 1.541.458 | 1,03% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6.869.846 | 1.431.218 | 0,95% | Ações |
| NORTHERN TRUST CORP | $6.811.315 | 1.419.024 | 0,95% | Ações |
| OSAIC HOLDINGS, INC. | $6.469.756 | 1.347.866 | 0,90% | Ações |
| ADAR1 Capital Management, LLC | $6.087.106 | 1.268.147 | 0,85% | Ações |
| Deltroit Asset Management (UK) LLP | $5.760.000 | 1.200.000 | 0,80% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $5.449.738 | 1.135.362 | 0,76% | Ações |
| CITIGROUP INC | $4.220.338 | 879.237 | 0,59% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3.771.945 | 838.210 | 0,52% | Ações |
| BANK OF MONTREAL /CAN/ | $3.734.102 | 777.938 | 0,52% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3.123.360 | 650.700 | 0,43% | Ações |
| MACKENZIE FINANCIAL CORP | $2.946.269 | 613.806 | 0,41% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2.889.638 | 602.008 | 0,40% | Ações |
| Western Standard LLC | $2.605.378 | 542.787 | 0,36% | Ações |
| Rangeley Capital, LLC | $2.400.000 | 500.000 | 0,33% | Ações |
| Nuveen, LLC | $2.383.723 | 496.609 | 0,33% | Ações |
| Man Group plc | $2.272.642 | 473.467 | 0,32% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $2.215.900 | 461.646 | 0,31% | Ações |
| Bank of New York Mellon Corp | $2.179.752 | 454.115 | 0,30% | Ações |
| CenterBook Partners LP | $2.136.725 | 445.151 | 0,30% | Ações |
| Freestone Capital Holdings, LLC | $2.124.000 | 442.500 | 0,30% | Ações |
| CITADEL ADVISORS LLC | $1.942.541 | 404.696 | 0,27% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $1.849.430 | 385.298 | 0,26% | Ações |
| D. E. Shaw & Co., Inc. | $1.832.942 | 381.863 | 0,25% | Ações |
| Swiss National Bank | $1.375.200 | 286.500 | 0,19% | Ações |
| Ledgewood Wealth Advisors, LLC | $1.336.493 | 278.436 | 0,19% | Ações |
| FMR LLC | $1.282.503 | 267.188 | 0,18% | Ações |
| Susquehanna Portfolio Strategies, LLC | $1.265.688 | 263.685 | 0,18% | Ações |
| Carrera Capital Advisors | $1.234.402 | 257.167 | 0,17% | Ações |
| Quinn Opportunity Partners LLC | $1.225.027 | 255.214 | 0,17% | Ações |
| Invesco Ltd. | $1.204.353 | 250.907 | 0,17% | Ações |
| UBS Group AG | $1.196.198 | 249.208 | 0,17% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.161.682 | 242.017 | 0,16% | Ações |
Ativistas e proprietários de 5%+ 8 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 declarações | 28 de Abril de 2026 | 8,00% | Emenda | · | SEC |
| Roivant Sciences Ltd. ×14 declarações | 25 de Fevereiro de 2025 | 20,50% | Emenda | · | SEC |
| Patrick Machado ×4 declarações | 17 de Julho de 2019 | · | Declaração inicial | · | SEC |
| Dr. Andrew Lo ×5 declarações | 17 de Julho de 2019 | · | Declaração inicial | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 declarações | 12 de Julho de 2019 | · | Declaração inicial | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 declarações | 12 de Julho de 2019 | · | Declaração inicial | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 declarações | 12 de Julho de 2019 | · | Declaração inicial | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 declarações | 12 de Julho de 2019 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 35 insiders · 17 diretores · 19 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | 18 de Setembro de 2026 M | 72.337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | 14 de Fevereiro de 2025 A | 1.658.003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | 1 de Fevereiro de 2023 A | 216.500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 de Março de 2019 A | 341.396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | 18 de Setembro de 2026 M | 159.963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 14 de Fevereiro de 2025 A | 249.824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 de Março de 2017 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | 14 de Fevereiro de 2025 A | 155.494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | 14 de Fevereiro de 2025 A | 140.544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 de Fevereiro de 2024 A | 1.485.121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | 1 de Fevereiro de 2023 A | 86.024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 20 de Janeiro de 2022 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 de Dezembro de 2018 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 de Abril de 2018 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 de Março de 2017 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 de Agosto de 2016 M | 42.097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 de Março de 2016 A | · | 0 | 0 | $0 |
| Roger Sawhney | Conselheiro | 18 de Setembro de 2026 M | 30.825 | 0 | 0 | $0 |
| Robert A Beardsley | Conselheiro | 18 de Setembro de 2026 M | 32.276 | 0 | 0 | $0 |
| Anuj Hasija | Conselheiro | 18 de Março de 2025 A | · | 0 | 0 | $0 |
| Keith S Manchester | Conselheiro | 14 de Agosto de 2024 M | 46.069 | 0 | 0 | $0 |
| Melissa Rewolinski | Conselheiro | 23 de Maio de 2024 A | · | 0 | 0 | $0 |
| Frank Torti | Conselheiro | 23 de Maio de 2024 A | · | 0 | 0 | $0 |
| James R Meyers | Conselheiro | 23 de Maio de 2024 A | · | 0 | 0 | $0 |
| Daniel D Burgess | Conselheiro | 23 de Maio de 2024 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | Conselheiro | 23 de Maio de 2024 A | 1.000 | 0 | 0 | $0 |
| Tram Tran | Conselheiro | 25 de Maio de 2022 A | · | 0 | 0 | $0 |
| Andrew Cheng | Conselheiro | 3 de Junho de 2021 A | · | 0 | 0 | $0 |
| Myrtle S Potter | Conselheiro | 17 de Agosto de 2019 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | Conselheiro | 19 de Junho de 2018 A | · | 0 | 0 | $0 |
| Herbert J Conrad | Conselheiro | 19 de Junho de 2018 A | · | 0 | 0 | $0 |
| Frank Karbe | Conselheiro | 21 de Junho de 2017 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Detentor de 10% | 18 de Outubro de 2021 C | 38.847.462 | 0 | 0 | $0 |
| Andrew Lo | Detentor de 10% | 12 de Janeiro de 2018 P | · | 0 | 0 | $0 |
| Patrick Machado | Detentor de 10% | 12 de Janeiro de 2018 P | · | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 26 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,68% | 72.962 NS | 31 de Julho de 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 521.191 NS | 31 de Julho de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,47% | 23.611 SH | 2 de Outubro de 2026 | Diário |
| IWC · iShares Trust | 0,19% | 545.721 SH | 11 de Setembro de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,11% | 124.896 NS | 31 de Julho de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 14.124 SH | 2 de Outubro de 2026 | Diário |
| IBB · iShares Trust | 0,06% | 1.201.130 SH | 11 de Setembro de 2026 | Diário |
| IWO · iShares Trust | 0,05% | 1.506.889 SH | 11 de Setembro de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172.487 SH | 19 de Agosto de 2026 | Diário |
| PWS · Pacer Funds Trust | 0,03% | 1.706 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 4.035.105 SH | 11 de Setembro de 2026 | Diário |
| RSSL · Global X Funds | 0,02% | 76.843 NS | 31 de Julho de 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 120.110 SH | 2 de Outubro de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925.044 SH | 19 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,01% | 24.707 SH | 11 de Setembro de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.810.587 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,01% | 430.244 SH | 19 de Agosto de 2026 | Diário |
| WSML · iShares Trust | 0,01% | 11.624 SH | 9 de Setembro de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 66.333 NS | 31 de Julho de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 265.986 SH | 11 de Setembro de 2026 | Diário |
| IWV · iShares Trust | 0,00% | 49.783 SH | 9 de Setembro de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.034.547 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.683 SH | 19 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | · | 6.673 SH | 11 de Setembro de 2026 | Diário |
| ISCV · iShares Trust | · | 13.314 SH | 11 de Setembro de 2026 | Diário |
| SMMV · iShares Trust | · | 60.845 SH | 1 de Setembro de 2026 | Diário |
ABUS Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 7 analistas
COMPRA
Alvo mediano
$5.39
+21,0%
3 42,9%
Compra forte
3 42,9%
Compra
1 14,3%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
1 analistas · 2026-09-28Alvo médio $5.39 +21,0%
Mín$5.39
Média$5.39
Máx$5.39
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 12, 2026